Legend Biotech Corporation

NASDAQ:LEGN

Biotechnology

Healthcare
$16.25 -13.51%

-$4.53 today

Market cap
$3.01B
Beta
0.35
P/E (TTM)
-21.4
EPS (TTM)
-$1.35
52W Low $16.24High $45.30

Volume 2.15M

Average 2.42M

LEGN Pre-Tax Margin

Income before tax as a percentage of revenue.

Legend Biotech CorporationNASDAQ: LEGN

Pre-Tax Margin · Q3 FY2026 · quarter ended Sep 2026

Pre-tax margin widens to 13.7%

Pre-tax margin was 13.7% in Q3 FY2026, up 28.1 pp from a year earlier. On a trailing-twelve-month basis it was 2.4%, up 26.8 pp year over year. Over 3 fiscal years it widened by 353.5 pp.

Context

  • Pre-tax margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
13.7%-0.6 pp QoQ
Last fiscal yearDec 2025
-27.5%-2.3 pp YoY
LTMSep 2026
2.4%+26.8 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+28.1 pp——
1 year-2.3 pp——
3 years+353.5 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-27.5%
Year-over-year change
-2.3pp

Pre-Tax Margin vs competitors

How LEGN compares with its peers on the latest reported figures

  • LEGN's LTM Sep 2026 pre-tax margin of 2.4% is the highest of the 10 companies compared; the peer median is -311.3%.
  • Its year-over-year change of +26.8 pp is the 4th highest of 10, against a peer median of -32.9 pp.
  • Over three fiscal years its change of +353.5 pp compares with a peer median of +154.5 pp.
LEGN Competitors Peer median
Pre-Tax Margin for LEGN and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 20262.4% +26.8 pp+353.5 pp
IPSCCentury Therapeutics, Inc.FY2025-8.8% +1884.9 pp+2507.8 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-40.8% -32.9 pp+386.2 pp
DTILPrecision BioSciences, Inc.LTM Mar 2026-98.7% -55.7 pp+154.5 pp
CLLSCellectis S.A.LTM Mar 2026-102.0% +24.5 pp+421.1 pp
AUTLAutolus Therapeutics plcLTM Mar 2026-311.3% +2289.7 pp+2005.7 pp
CRBUCaribou Biosciences, Inc.LTM Mar 2026-1194.0% +296.9 pp-615.0 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2056.8% -737.9 pp-1758.5 pp
RNACCartesian Therapeutics, Inc.LTM Mar 2026-9068.6% -8957.3 pp-5018.7 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-794858.1% -280208.8 pp-762139.3 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding LEGN) -311.3%-32.9 pp+154.5 pp

Competitors are the stored peer set for LEGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue68.83M117.01M285.14M627.24M1.03B
Cost of Revenue065.36M144.21M234.58M408.1M
Gross Profit68.83M51.64M140.93M392.66M620.8M
Gross Margin100.0%44.1%49.4%62.6%60.3%
Research & Development313.35M335.65M382.22M413.54M414.7M
Selling, General & Admin149.5M174.05M200.93M284.26M341.6M
Operating Expenses461.11M507.26M580.41M695.9M757.3M
Depreciation & Amortization13.92M18.39M20.45M23.36M28.9M
EBITDA(392.38M)(416.54M)(477.87M)(113.16M)(232.3M)
EBITDA Margin-570.1%-356.0%-167.6%-18.0%-22.6%
Operating Income(392.29M)(455.62M)(439.49M)(303.24M)(136.5M)
Operating Margin-570.0%-389.4%-154.1%-48.3%-13.3%
Interest Income971K8.18M54.49M61.2M40.1M
Interest Expense900K10.8M21.79M21.62M21.4M
Other Income / Expenses(14.91M)9.9M(80.63M)145.11M(146.1M)
Income Before Tax(407.2M)(445.72M)(520.12M)(158.13M)(282.6M)
Pre-Tax Margin-591.6%-380.9%-182.4%-25.2%-27.5%
Income Tax Expense(3.61M)625K(1.86M)18.89M14.2M
Net Income(403.58M)(446.35M)(518.25M)(177.03M)(296.8M)
Net Margin-586.4%-381.5%-181.8%-28.2%-28.8%
EPS (Basic)(2.74)(2.81)(2.94)(0.97)(1.60)
EPS (Diluted)(2.74)(2.81)(2.94)(0.97)(1.60)
Weighted Avg Shares140.85M159.04M176.08M182.85M184.32M
Weighted Avg Shares (Diluted)140.85M159.04M176.08M182.85M184.32M

Legend Biotech Corporation

NASDAQ:LEGN

Intrinsic Alpha fair value

Locked

Current Price

$16.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.